Skip to main content
SpringerLink
Log in

Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: initial experience

  • Short communication
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Purpose

The aim of this study was to report our early experience with 18F-fluoride PET/CT for detecting lesions and evaluate the usefulness of this modality in the assessment of multiple myeloma (MM).

Materials and methods

18F-fluoride PET/CT and 99mTc-MDP bone scintigraphy (BS) studies from 7 myeloma patients (4 male and 3 female, mean age 55 years) diagnosed according to standard criteria were reviewed retrospectively. Two reviewers visually and quantitatively analyzed the images and recorded their findings after reaching a consensus. Diagnostic certainty regarding the presence or absence of myeloma lesions was evaluated according to the reference standard consisting of whole-body magnetic resonance imaging and whole-body X-ray.

Results

A total of 93 affected areas were definite according to the reference standard. Of these, 83 affected areas (89 %) were identified on 18F-fluoride PET/CT, whereas 54 affected areas (58 %) were found on BS. Mean SUVmax in the affected areas was 9.8 ± 3.2 (standard deviation) ranging from 5.0 to 21.2. A total of s17 lesions with bone fracture were also detected by 18F-fluoride PET/CT and 2 lesions (12 %) were negative on BS.

Conclusion

Our result showed that 18F-fluoride PET was a possible modality to detect areas of lesions in patients with MM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Durie BG, Waxman AD, D’Agnolo A, Williams CM. Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med. 2002;43:1457–63.

    PubMed  Google Scholar 

  2. Smith A, Wisloff F, Samson D, Myeloma Forum UK, Nordic Myeloma Study Group. British Committee for Standards in Haematology: guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006;132:410–51.

    Article  PubMed  Google Scholar 

  3. Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42:1539–43.

    Article  PubMed  Google Scholar 

  4. D’Sa S, Abildgaard N, Tighe J, Shaw P, Hall-Craggs M. Guidelines for the use of imaging in the management of myeloma. Br J Haematol. 2007;137:49–63.

    PubMed  Google Scholar 

  5. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F fluorodeoxyglucose positron emission tomography–computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50–5.

    Article  PubMed  Google Scholar 

  6. Nanni C, Zamagni E, Farsad M, Castellucci P, Tosi P, Cangini D, et al. Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging. 2006;33:525–31.

    Article  PubMed  Google Scholar 

  7. Ludwig H, Kupman W, Sinzinger H. Radiography and bone scintigraphy in multiple myeloma: a comparative analysis. Br J Radiol. 1982;55:173–81.

    Article  PubMed  CAS  Google Scholar 

  8. Bataille R, Chevalier J, Rossi M, et al. Bone scintigraphy in plasma cell myeloma. A prospective study of 70 patients. Radiology. 1982;145:801–4.

    PubMed  CAS  Google Scholar 

  9. Breyer RJ 3rd, Mulligan ME, Smith SE, et al. Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma. Skeletal Radiol. 2006;35:632–40.

    Article  PubMed  Google Scholar 

  10. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18F-FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118:5989–95.

    Article  PubMed  CAS  Google Scholar 

  11. Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68–78.

    Article  PubMed  Google Scholar 

  12. Hawkins RA, Choi Y, Huang SC, Hoh CK, Dahlbom M, Schiepers C, et al. Evaluation of skeletal kinetics of fluorine 18-fluoride ion and PET. J Nucl Med. 1992;33:633–42.

    PubMed  CAS  Google Scholar 

  13. Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45:272–8.

    PubMed  Google Scholar 

  14. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the international myeloma foundation. Hematol J. 2003;4:379–98.

    Article  PubMed  Google Scholar 

  15. Even-Sapir Ammeter U, Mishani E, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–97.

    Google Scholar 

Download references

Acknowledgments

This work was supported (in part) by a Grant-in-Aid for Cancer Research (21-5-2) from the Ministry of Health, Labour and Welfare.

Author information

Authors and Affiliations

  1. Departments of Radiology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan

    Yuji Nishiyama, Ukihide Tateishi, Kazuya Shizukuishi, Ayako Shishikura, Hiroto Shibata, Tomohiro Yoneyama & Tomio Inoue

  2. Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

    Etsuko Yamazaki & Yoshiaki Ishigatsubo

Authors
  1. Yuji Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ukihide Tateishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuya Shizukuishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayako Shishikura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Etsuko Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroto Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomohiro Yoneyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yoshiaki Ishigatsubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomio Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ukihide Tateishi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nishiyama, Y., Tateishi, U., Shizukuishi, K. et al. Role of 18F-fluoride PET/CT in the assessment of multiple myeloma: initial experience. Ann Nucl Med 27, 78–83 (2013). https://doi.org/10.1007/s12149-012-0647-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-012-0647-7

Keywords

Search

Navigation